We are live on ! Find out more
GWPH

GW Pharmaceuticals Plc American Depositary Shares
GWPH

Delisted

GWPH was delisted on the 4th of May, 2021.

87 hedge funds and large institutions have $884M invested in GW Pharmaceuticals Plc American Depositary Shares in 2014 Q2 according to their latest regulatory filings, with 36 funds opening new positions, 31 increasing their positions, 11 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

182% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 11

125% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 16

98% more capital invested

Capital invested by funds: $446M → $884M (+$438M)

50% more funds holding in top 10

Funds holding in top 10: 23 (+1)

28% more funds holding

Funds holding: 6887 (+19)

11% less call options, than puts

Call options by funds: $45.5M | Put options by funds: $51M

Holders
87
Holders Change
+19
Holders Change %
+27.94%
% of All Funds
2.5%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.09%
New
36
Increased
31
Reduced
11
Closed
16
Calls
$45.5M
Puts
$51M
Net Calls
-$5.47M
Net Calls Change
-$5.52M
Name Holding Trade Value Shares
Change
Change in
Stake
HI
76
Hudock Inc
Pennsylvania
$13K +$8.35K +120 New
MSFP
77
Mark Sheptoff Financial Planning
Connecticut
$11K
Bessemer Group
78
Bessemer Group
New Jersey
$11K +$6.95K +100 New
SGC
79
South Georgia Capital
Illinois
$11K +$6.95K +100 New
VIA
80
Vantage Investment Advisors
Pennsylvania
$11K +$6.95K +100 New
ARMC
81
American Research & Management Company
Massachusetts
$5K
WA
82
WFG Advisors
Texas
$5K
RFA
83
Reilly Financial Advisors
California
$5K +$3.48K +50 New
MCM
84
Manchester Capital Management
Vermont
$4K +$2.36K +34 New
TCM
85
Tradewinds Capital Management
Washington
$3K +$1.74K +25 New
PFG
86
Piershale Financial Group
Illinois
$2K -$139 -2 -10%
RG
87
Redmile Group
California
-$19.2M -323,583 Closed
A
88
Abingworth
United Kingdom
-$6.07M -102,200 Closed
O
89
OrbiMed
New York
-$5.67M -95,500 Closed
TCP
90
Tourbillon Capital Partners
New York
-$3.33M -56,000 Closed
PP
91
PDT Partners
New York
-$2.22M -37,411 Closed
ARTA
92
A.R.T. Advisors
New York
-$1.87M -31,548 Closed
TI
93
Turner Investments
Pennsylvania
-$1.45M -24,470 Closed
RSCM
94
Rock Springs Capital Management
Maryland
-$1.05M -17,750 Closed
CCI
95
Columbus Circle Investors
-$995K -16,761 Closed
UM
96
Ulysses Management
New York
-$576K -9,700 Closed
SG Americas Securities
97
SG Americas Securities
New York
-$410K -6,900 Closed
TD Asset Management
98
TD Asset Management
Ontario, Canada
-$392K -6,600 Closed
BACM
99
Blue Arrow Capital Management
New York
-$297K -5,000 Closed
LFG
100
LifePlan Financial Group
Ohio
-$11K -182 Closed

GWPH Hedge Fund Activity: Q2 2014 in Review

87 of the 3,480 institutional investors tracked by Wall St. Rank reported a position in GW Pharmaceuticals Plc American Depositary Shares (GWPH) for Q2 2014, worth a combined $884M — up 98% from $446M a quarter earlier.

Buyers outnumbered sellers: 36 funds opened new GWPH positions and 16 closed out — a net gain of 20 holders — while 31 added to existing stakes and 11 trimmed.

The largest buyer was Capital Research Global Investors, adding an estimated $73.3M. The largest seller was VHCP Management, cutting an estimated $23.1M.

  • 87 institutional investors held GW Pharmaceuticals Plc American Depositary Shares (GWPH) as of Q2 2014, up from 68 in Q1 2014.
  • Funds reported $884M of GW Pharmaceuticals Plc American Depositary Shares stock for Q2 2014, up 98% quarter-over-quarter.
  • 36 funds opened new GW Pharmaceuticals Plc American Depositary Shares positions in Q2 2014 and 16 closed out, a net change of +20 holders.
  • The largest GW Pharmaceuticals Plc American Depositary Shares buyer in Q2 2014 was Capital Research Global Investors, an estimated $73.3M added.
  • The largest GW Pharmaceuticals Plc American Depositary Shares seller in Q2 2014 was VHCP Management, an estimated $23.1M sold.

Based on aggregated 13F filings for Q2 2014.